Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114582 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL21835483 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL15114584 | 0.84 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL2123962 | 0.84 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL15113993 | 0.83 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL1574379 | 0.83 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL23245696 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL25712548 | 0.79 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HPGDPREP | |
| SCHEMBL2127479 | 0.77 | KDM4E (0.44) | KDM4E | |
| SCHEMBL15116715 | 0.77 | TSHR (0.33) | USP2HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CHRM2 4882/4885CHRM1 4873/4885CHRM3 4802/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CHRM2 4882/4885CHRM1 4873/4885CHRM3 4802/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CHRM2 4882/4885CHRM1 4873/4885CHRM3 4802/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CHRM2 4882/4885CHRM1 4873/4885CHRM3 4802/4885 |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | CHRM2 2988/4885CHRM1 1791/4885CHRM3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.